Do you want to read an article? Please log in or register.
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials
Lipid-Lowering Drugs
Related content
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
J Am Heart Assoc.
Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP
doi: 10.1161/JAHA.117.005639.
Lipid-Lowering Drugs
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
Cardiovasc Drugs Ther.
Bays HE, Rosenson RS, Baccara-Dinet MT, Louie MJ, Thompson D, Hovingh GK
doi: 10.1007/s10557-018-6784-z.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsTherapy and Intervention
Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
Atherosclerosis.
Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C
doi: 10.1016/j.atherosclerosis.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M
doi: 10.1161/JAHA.119.014129.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Atherosclerosis.
Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP
doi: 10.1016/j.atherosclerosis.2019.06.896.
Cardiovascular Risk and Diseases
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
JAMA.
Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG, BETonMACE Investigators and Committees.
doi: 10.1001/jama.2020.3308.
Lipid-Lowering Drugs
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial
JAMA Cardiol.
Nicholls SJ, Puri R, Ballantyne CM, Jukema JW, Kastelein JJP, Koenig W, Wright RS, Kallend D, Wijngaard P, Borgman M, Wolski K, Nissen SE
doi: 10.1001/jamacardio.
Lipid-Lowering Drugs
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.
J Am Coll Cardiol.
Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller K, Kastelein JJ
doi: 10.1016/j.jacc.2016.11.037.
RECOMMENDED
Lipid-Lowering Drugs
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control
Atherosclerosis.
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP
doi: 10.1016/